<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740714</url>
  </required_header>
  <id_info>
    <org_study_id>U01NS050324</org_study_id>
    <secondary_id>U01NS050573</secondary_id>
    <nct_id>NCT00740714</nct_id>
  </id_info>
  <brief_title>Effects of Coenzyme Q10 (CoQ) in Parkinson Disease</brief_title>
  <acronym>QE3</acronym>
  <official_title>Effects of Coenzyme Q10 in Parkinson Disease - Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of high dosages of
      Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson disease (PD) is a progressive neurodegenerative disease that affects more than
      1,000,000 Americans. Currently there is no proven therapy to reduce the rate of progression
      of PD. In a previous phase II clinical trial, investigators demonstrated that Coenzyme Q10
      (CoQ) at dosages of 300, 600, and 1200 mg/day was safe and well-tolerated in individuals with
      early, untreated PD. The findings also suggested that CoQ may slow the progressive impairment
      of PD as measured by the Unified Parkinson Disease Rating Scale (UPDRS).

      In this study, researchers will conduct a randomized, placebo-controlled, phase III trial of
      CoQ to confirm and extend the results of the earlier phase II study. The primary objective of
      this trial is to compare the effect of two dosages of CoQ (1200 and 2400 mg/day) and placebo
      on the total UPDRS score in people with early PD. The study also will evaluate independent
      function, cognition, and quality of life. Plasma CoQ levels will be measured at months 1, 8
      and 16 and correlated with changes in UPDRS scores.

      Participants will be randomly assigned to receive a placebo (an inactive substance), 1200
      mg/d CoQ, or 2400 mg/d CoQ. They will be evaluated at screening, baseline, and during visits
      at months 1, 4, 8, 12, and 16. Information gained from this trial could lead to changes in
      management of people with early PD.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The investigational drug is unlikely to demonstrate efficacy over placebo for this indication.
    However, no safety issues were discovered.
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Schwab &amp; England Independence Scale From Baseline to 16 Months</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Rankin Scale From Baseline to 16 Months</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD Quality of Life Scale From Baseline to 16 Months</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symbol Digit Modalities Test From Baseline to 16 Months</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hoehn &amp; Yahr Score From Baseline to 16 Months</measure>
    <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CoQ10 Levels in Plasma</measure>
    <time_frame>Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
    <description>Based on samples analyzed to date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Back Pain</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Constipation</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Insomnia</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with insomnia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Anxiety</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Tremor</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with tremor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Nasopharyngitis</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with nasopharyngitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Diarrhoea</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with diarrhoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Headache</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Urinary Tract Infection</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of patients with urinary tract infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Nausea</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Hypertension</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Depression</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Constipation: Moderate/Severe</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with moderate/severe constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Anxiety: Moderate/Severe</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with moderate/severe anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Back Pain: Moderate/Severe</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with moderate/severe back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences: Insomnia: Moderate/Severe</measure>
    <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
    <description>Number of participants with moderate/severe insomnia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (with vitamin E 1200 IU/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10 with vitamin E</intervention_name>
    <description>2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Coenzyme Q10, ubiquinone, ubidecarenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo with vitamin E</intervention_name>
    <description>placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of all 3 of the cardinal features of Parkinson disease (resting tremor,
             bradykinesia and rigidity). The clinical signs must be asymmetric.

          -  The diagnosis of Parkinson disease within 5 years prior to the Screening Visit.

          -  Age 30 or older.

          -  Female subjects must not be of childbearing potential or must use an approved form of
             contraception for the duration of the trial.

        Exclusion Criteria:

          -  Use of any Parkinson disease medication within 60 days prior to the Baseline Visit.

          -  Duration of previous use of symptomatic medication for Parkinson disease cannot exceed
             90 days such as levodopa, dopaminergic agonists (including ropinirole, pramipexole,
             pergolide, cabergoline, and the rotigotine transdermal system), selegiline,
             rasagiline, amantadine, and anticholinergic agents.

          -  Parkinsonism due to drugs including neuroleptics, alphamethyldopa, reserpine,
             metoclopramide, valproic acid.

          -  Use of antioxidants (such as selegiline, rasagiline, vitamins E and C), additional
             supplemental vitamins or minerals, regular use of neuroleptics, chloramphenicol,
             valproic acid, warfarin.

          -  Other parkinsonian disorders.

          -  Modified Hoehn and Yahr score of 3 or greater at Screening Visit or Baseline Visit.

          -  UPDRS tremor score of 3 or greater at Screening Visit or Baseline Visit.

          -  Mini-Mental State Examination (MMSE) score of 25 or less.

          -  History of stroke.

          -  Disability sufficient to require treatment with dopaminergic medication or anticipated
             need for dopaminergic medication within next 3 months.

          -  Other serious illness, including psychiatric illness.

          -  Patients with active cardiovascular, peripheral vascular or cerebrovascular disease
             within the past year.

          -  Clinically serious abnormalities in the Screening Visit laboratory studies or
             electrocardiogram.

          -  Use of methylphenidate, cinnarizine, reserpine, amphetamine or a MAO-A inhibitor
             within 6 months prior to the Baseline Visit.

          -  Unstable dose of CNS active therapies.

          -  Use of appetite suppressants within 60 days prior to the Baseline Visit.

          -  History of active epilepsy within the last 5 years.

          -  Revised Hamilton Rating Scale for Depression of 11 or greater.

          -  Participation in other drug studies or use of other investigational drugs within 30
             days prior to Screening Visit.

          -  History of electroconvulsive therapy.

          -  History of any brain surgery for Parkinson disease.

          -  History of structural brain disease such as prior trauma causing damage detected on a
             CT scan or MRI, hydrocephalus, or prior brain neoplasms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Flint Beal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University, New York Hospital Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Oakes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester, Department of Biostatistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ira Shoulson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester, Clinical Trials Coordination Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham, 350 Sparks Center, 1720 7Th Avenue South</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Clinics At St Joseph`S Hospital &amp; Medical Center, 500 West Thomas Road Suite 720</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona, 13400 East Shea Boulevard, Desk 34 3B</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunhealth Research Institute, 10515 West Santa Fe Drive</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinson'S &amp; Movement Disorder Institute, 9940 Talbert Avenue, Suite 204</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine, 100 Irvine Hall</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-4275</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego, Alzheimer'S Disease Research Center, 9500 Gilman Drive</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0948</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center, 710 Westwood Plaza, A-253</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Dept of Neurology, 4860 Y Street, Suite 3700</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinson's Institute, 675 ALMANOR AVENUE</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology/Mail Stop B185, 12631 East 17Th Avenue Room 5209, Academic Office 1 Po Box 6511</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute, 701 East Hampden Avenue, Suite 510</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute For Neurodegenerative Disorders, 60 Temple Street, Suite 8B</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, McKnight Brain Institute Po Box 100236, 100 S Newell Drive L3-100</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610-5806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, 1501 North West 9Th Avenue Second Floor, Department of Neurology D4-5</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, 4 Columbia Drive, Suite 410</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road NE Room 328</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Program, Department of Neurology, Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University, 710 North Lake Shore Drive</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center Department of Neurological Sciences, 1725 West Harrison Suite 755</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago, 5841 South Maryland Avenue, Mc2030</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals, 2133 Rcp Department of Neurology, 200 Hawkins Drive</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center, Department of Neurology Ms #2012, 3599 Rainbow Boulevard</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Movement Disorder Clinic, Frazier Rehab, 220 Abraham Flexner, Suite 606</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation, 1514 Jefferson Highway, Dept of Neurology 7Th Floor</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lsuhsc Shreveport, Department of Neurology, 1501 Kings Highway Room 3-436</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins, 601 North Caroline Street, Suite 5064</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson &amp; Movement Dis Center If Maryland, 8180 Lark Brown Road, Suite 101</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center, Department of Neurology, 715 Albany Street C329</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Shapiro 809D</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, 420 Delaware Street SE, Mmc 295</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, 660 South Euclid, Box 8111</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College, Parkinson'S Disease &amp; Movement Disorders Ctr, 47 New Scottland Avenue</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JACOBI MEDICAL CENTER, 1400 Pelham Pkwy S</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suny Downstate Medical Center , 450 Clarkson Avenue , Box 1213</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore-Lij Health System, the Feinstein Institute Fpr Medical Research, 350 Community Drive Room 100</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center, 10 Union Square East, Suite 5Hh2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East Room 5Ho1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson`S Dis &amp; Movement Disorders Inst, 428 East 72Nd Street, Suite 400</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, 710 West 168Th Street, 3Rd Floor</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Department of Neurology, 919 Westfall Road Building C Suite 220</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke Health Center At Morreene Road, 932 Morreene Road Room 213</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Neurology Inc., 222 Piedmont Avenue, Suite 3200</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation, 9500 Euclid Avenue S-31</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center, 1581 Dodd Drive, 371 McCampbell Hall</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo , 3000 Arlington Avenue , Mail Stop 1195</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University, Dept of Neurology, 3181 SW Sam Jackson Park Road Op-32</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Med Center, Department of Neurology Mc H109 Room 2846, 500 University Drive Po Box 850</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Pennsylvania Hospital Department of Neurology, 330 South 9Th Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurohealth Parkinson'S Disease, Movement Disorder Center, 227 Centerville Road</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Charleston Memorial Hospital, 326 Calhoun Street Suite 308</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmes Murphey Clinic, 1211 Union Avenue, Suite 200</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Parkinson'S, Disease Center and Movement Disorders Clinic, 65501 Fannin St, Suite 1801</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson'S Care Center, 13030 121St Way North East Suite 203</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Department of Neurology, 9200 West Wisconsin Avenue</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-0099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Un of Calgary Movement Disorders Program, Dept of Clin Neurosciences Area 3 Neurology, 3350 Hospital Dr NW Health Sciences Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4NI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Glenrose Rehab Hosp, Rm 0601 Glen East, 10230 - 111 Avenue</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5G 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Campus Room 10N29, 339 Windermere Road</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital-Civic Campus, 1053 Carling Avenue C2 Room 2210</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital, Univ Health Network, 399 Bathurst Street Mc 7-402, Movement Disorders Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-HOPITAL NOTRE DAME, 1560 rue SHERBROOKE est ROOM GR 1185, PAVILLON DECHAMPS etage rez-de-chaussee</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke, 3001 12E Avenue Nord</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital, 103 Hospital Drive, Room 1663</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N OW8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quebec Memory and Motor Skills Dis Clinic, Price Building 3Rd Floor, 65 Sainte-Anne Street</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 3X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994 Dec;36(6):882-8.</citation>
    <PMID>7998775</PMID>
  </reference>
  <reference>
    <citation>Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998 Feb 2;783(1):109-14.</citation>
    <PMID>9479058</PMID>
  </reference>
  <reference>
    <citation>Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 2000 Jul;23(7):298-304. Review.</citation>
    <PMID>10856939</PMID>
  </reference>
  <reference>
    <citation>Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res. 2002 Apr;36(4):455-60. Review.</citation>
    <PMID>12069110</PMID>
  </reference>
  <reference>
    <citation>NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20-8.</citation>
    <PMID>17200487</PMID>
  </reference>
  <reference>
    <citation>Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003 Apr 22;60(8):1234-40. Review.</citation>
    <PMID>12707423</PMID>
  </reference>
  <reference>
    <citation>Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May;51(5):604-12.</citation>
    <PMID>12112107</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997 Aug;42(2):261-4.</citation>
    <PMID>9266740</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998 Mar;50(3):793-5.</citation>
    <PMID>9521279</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.</citation>
    <PMID>12374491</PMID>
  </reference>
  <reference>
    <citation>Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem. 2003 Oct;10(19):1917-21. Review.</citation>
    <PMID>12871093</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004 Aug;188(2):491-4.</citation>
    <PMID>15246848</PMID>
  </reference>
  <reference>
    <citation>Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005 Jul 6;294(1):56-65.</citation>
    <PMID>15998891</PMID>
  </reference>
  <reference>
    <citation>Blatt DH, Pryor WA. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005 Jul 19;143(2):150-1; author reply 156-8.</citation>
    <PMID>16027460</PMID>
  </reference>
  <reference>
    <citation>McDonald SR, Sohal RS, Forster MJ. Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med. 2005 Mar 15;38(6):729-36.</citation>
    <PMID>15721983</PMID>
  </reference>
  <reference>
    <citation>Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005 Jan 4;142(1):37-46. Epub 2004 Nov 10.</citation>
    <PMID>15537682</PMID>
  </reference>
  <reference>
    <citation>Miller E. R., Appel L. J., Guallar E., and Pastor-Barriuso R. High-Dosage Vitamin E Supplementation and All-Cause Mortality. Ann Intern Med. 2005b, 143:156-158.</citation>
  </reference>
  <reference>
    <citation>Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 Jan 21;328(3):176-83.</citation>
    <PMID>8417384</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <results_first_submitted>July 24, 2012</results_first_submitted>
  <results_first_submitted_qc>December 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 31, 2013</results_first_posted>
  <last_update_submitted>December 24, 2012</last_update_submitted>
  <last_update_submitted_qc>December 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>PD</keyword>
  <keyword>Coenzyme Q10</keyword>
  <keyword>CoQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for the required 600 patients was from January 2009 to October 2010. There were 67 sites (60 in the US and 7 in Canada) that participated in the study. Most of these sites were located at or affiliated with large academic medical centers.</recruitment_details>
      <pre_assignment_details>Patients were required to undergo a thorough screening visit. If patients were taking CoEnzyme Q10 but otherwise eligible for assignment, they were asked to return after a wash out period of 60 to 120 days based on daily dosage.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="P2">
          <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="P3">
          <title>C. Placebo With Vitamin E 1200 IU/Day</title>
          <description>Placebo (with vitamin E 1200 IU/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="196">Randomized throughout the recruitment period</participants>
                <participants group_id="P2" count="201">Randomized throughout the recruitment period</participants>
                <participants group_id="P3" count="203">Randomized throughout the recruitment period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reaching Endpoint Before May 6, 2011</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Active Patients at Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="182"/>
                <participants group_id="P3" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="B2">
          <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="B3">
          <title>C. Placebo With Vitamin E 1200 IU/Day</title>
          <description>Placebo (with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="196"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="203"/>
            <count group_id="B4" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="9.66"/>
                    <measurement group_id="B2" value="63.3" spread="9.83"/>
                    <measurement group_id="B3" value="61.3" spread="10.5"/>
                    <measurement group_id="B4" value="62.5" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))</title>
        <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176.</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>Eligible research participants were assigned by randomization to one of three treatment groups: CoQ10 2400 mg/day, CoQ10 1200 mg/day or matching placebo. All participants also received 1200 IU of vitamin E daily.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))</title>
          <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176.</description>
          <population>Eligible research participants were assigned by randomization to one of three treatment groups: CoQ10 2400 mg/day, CoQ10 1200 mg/day or matching placebo. All participants also received 1200 IU of vitamin E daily.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread=".63"/>
                    <measurement group_id="O2" value="7.50" spread=".62"/>
                    <measurement group_id="O3" value="6.92" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA is used with the change in total UPDRS of Coenzyme Q10 1200 mg/day arm compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.025</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-values for efficacy outcomes will be 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA is used with the change in total UPDRS of Coenzyme Q10 2400 mg/day arm compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.025</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-values for efficacy outcomes will be 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Schwab &amp; England Independence Scale From Baseline to 16 Months</title>
        <description>This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden).</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants were used in primary and secondary outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Schwab &amp; England Independence Scale From Baseline to 16 Months</title>
          <description>This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden).</description>
          <population>All participants were used in primary and secondary outcome analyses.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread=".62"/>
                    <measurement group_id="O2" value="-4.29" spread=".62"/>
                    <measurement group_id="O3" value="-4.07" spread=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Modified Schwab &amp; England will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7943</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month on Modified Schwab &amp; England will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.79</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Rankin Scale From Baseline to 16 Months</title>
        <description>The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention.</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants were used in primary and secondary outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Rankin Scale From Baseline to 16 Months</title>
          <description>The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention.</description>
          <population>All participants were used in primary and secondary outcome analyses.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".38" spread=".05"/>
                    <measurement group_id="O2" value=".31" spread=".05"/>
                    <measurement group_id="O3" value=".40" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Modified Rankin Scale will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.1615</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Modified Rankin will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7627</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-Adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plats and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PD Quality of Life Scale From Baseline to 16 Months</title>
        <description>The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life.</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants were used in primary and secondary outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PD Quality of Life Scale From Baseline to 16 Months</title>
          <description>The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life.</description>
          <population>All participants were used in primary and secondary outcome analyses.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread=".89"/>
                    <measurement group_id="O2" value="6.12" spread=".87"/>
                    <measurement group_id="O3" value="5.57" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on PD Quality of Life Scale will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6383</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6383</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on PD Quality of Life Scale will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symbol Digit Modalities Test From Baseline to 16 Months</title>
        <description>The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants were used in primary and secondary outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symbol Digit Modalities Test From Baseline to 16 Months</title>
          <description>The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
          <population>All participants were used in primary and secondary outcome analyses.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="1.40"/>
                    <measurement group_id="O2" value="-0.49" spread="1.39"/>
                    <measurement group_id="O3" value="-3.02" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Symbol Digit Modalities Test will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.14</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Symbol Digit Modalities Test will be analyzed using ANCOVA in the same way as for the primary outcome variable</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.34</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hoehn &amp; Yahr Score From Baseline to 16 Months</title>
        <description>The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided).</description>
        <time_frame>Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants were used in primary and secondary outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hoehn &amp; Yahr Score From Baseline to 16 Months</title>
          <description>The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided).</description>
          <population>All participants were used in primary and secondary outcome analyses.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".21" spread="0.03"/>
                    <measurement group_id="O2" value=".20" spread="0.03"/>
                    <measurement group_id="O3" value=".16" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline Visit to 16-month visit on Hoehn &amp; Yahr Score will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3445</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided, with a Bonferroni-adjusted significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assessed with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline visit to 16-month visit on Hoehn &amp; Yahr will be analyzed using ANCOVA in the same way as for the primary outcome variable.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.239</p_value>
            <p_value_desc>The primary analysis compares each active treatment arm to the placebo arm. P-Values for efficacy outcomes are 2-sided. with a Bonferroni-adjustd significance level of .025 used to preserve the overall alpha level for the 2 comparisons at .05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>COCF is used for missing data and those lost to follow up. Outliers and non-compliant patients are assess with scatter and residual plots and ITT.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CoQ10 Levels in Plasma</title>
        <description>Based on samples analyzed to date</description>
        <time_frame>Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first</time_frame>
        <population>All participants have been included and data is based on samples analyzed to date.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>CoQ10 Levels in Plasma</title>
          <description>Based on samples analyzed to date</description>
          <population>All participants have been included and data is based on samples analyzed to date.</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="1.83"/>
                    <measurement group_id="O2" value="2.57" spread="1.29"/>
                    <measurement group_id="O3" value=".75" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="1.93"/>
                    <measurement group_id="O2" value="2.67" spread="1.33"/>
                    <measurement group_id="O3" value="1.07" spread=".83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="2.02"/>
                    <measurement group_id="O2" value="2.17" spread="1.18"/>
                    <measurement group_id="O3" value=".63" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis will be using the actual change of plasma levels of CoQ10(from final visit to baseline) as predictors of UPDRS worsening. Correlation of UPDRS worsening with plasma levels of CoQ10 will be calculated for all treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0577</p_value>
            <method>ANOVA</method>
            <method_desc>The ANOVA is using UPDRS worsening as outcome, Change of CoQ10 level as predictor, adjusting for site and baseline UPDRS score.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.536</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.282</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>1.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The analysis will be using the actual change of plasma levels of CoQ10(from final to baseline) as predictors of UPDRS worsening. Correlation of UPDRS worsening with plasma levels of CoQ10 will be calculated for the treatment group of Coenzyme Q10 2400 mg/day.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5889</p_value>
            <method>ANOVA</method>
            <method_desc>The ANOVA is using UPDRS worsening as outcome, Change of CoQ10 level as predictor, adjusting for site and baseline UPDRS score.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.245</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.451</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.647</ci_lower_limit>
            <ci_upper_limit>1.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will be using the actual change of plasma levels of CoQ10(from final to baseline) as predictors of UPDRS worsening. Correlation of UPDRS worsening with plasma levels of CoQ10 will be calculated for the treatment group of Coenzyme Q10 1200 mg/day.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3006</p_value>
            <method>ANOVA</method>
            <method_desc>The ANOVA is using UPDRS worsening as outcome, Change of CoQ10 level as predictor, adjusting for site and baseline UPDRS score.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.631</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.608</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.569</ci_lower_limit>
            <ci_upper_limit>1.831</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The analysis will be using the actual change of plasma levels of CoQ10(from final to baseline) as predictors of UPDRS worsening. Correlation of UPDRS worsening with plasma levels of CoQ10 will be calculated for the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>ANOVA</method>
            <method_desc>The ANOVA is using UPDRS worsening as outcome, Change of CoQ10 level as predictor, adjusting for site and baseline UPDRS score.</method_desc>
            <param_type>Slope</param_type>
            <param_value>2.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.269</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.382</ci_lower_limit>
            <ci_upper_limit>4.633</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Back Pain</title>
        <description>Number of participants with back pain</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Back Pain</title>
          <description>Number of participants with back pain</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Constipation</title>
        <description>Number of participants with constipation</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Constipation</title>
          <description>Number of participants with constipation</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subject experiencing a particular adverse experience</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0198</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Insomnia</title>
        <description>Number of participants with insomnia</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Insomnia</title>
          <description>Number of participants with insomnia</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0198</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>4.20</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Anxiety</title>
        <description>Number of participants with anxiety</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Anxiety</title>
          <description>Number of participants with anxiety</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Tremor</title>
        <description>Number of participants with tremor</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Tremor</title>
          <description>Number of participants with tremor</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Nasopharyngitis</title>
        <description>Number of participants with nasopharyngitis</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Nasopharyngitis</title>
          <description>Number of participants with nasopharyngitis</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>9.72</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Diarrhoea</title>
        <description>Number of participants with diarrhoea</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Diarrhoea</title>
          <description>Number of participants with diarrhoea</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Headache</title>
        <description>Number of participants with headache</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Headache</title>
          <description>Number of participants with headache</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Urinary Tract Infection</title>
        <description>Number of patients with urinary tract infections</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Urinary Tract Infection</title>
          <description>Number of patients with urinary tract infections</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>8.58</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Nausea</title>
        <description>Number of participants with nausea</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Nausea</title>
          <description>Number of participants with nausea</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Hypertension</title>
        <description>Number of participants with hypertension</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Hypertension</title>
          <description>Number of participants with hypertension</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9999.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.77</ci_lower_limit>
            <ci_upper_limit>9999.99</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Depression</title>
        <description>Number of participants with depression</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Depression</title>
          <description>Number of participants with depression</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Odds ration &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Constipation: Moderate/Severe</title>
        <description>Number of participants with moderate/severe constipation</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Constipation: Moderate/Severe</title>
          <description>Number of participants with moderate/severe constipation</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>8.01</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Anxiety: Moderate/Severe</title>
        <description>Number of participants with moderate/severe anxiety</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Anxiety: Moderate/Severe</title>
          <description>Number of participants with moderate/severe anxiety</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0198</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
            <estimate_desc>Odds ratio of &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Back Pain: Moderate/Severe</title>
        <description>Number of participants with moderate/severe back pain</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Back Pain: Moderate/Severe</title>
          <description>Number of participants with moderate/severe back pain</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9999.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0197</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>9999.99</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences: Insomnia: Moderate/Severe</title>
        <description>Number of participants with moderate/severe insomnia</description>
        <time_frame>Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)</time_frame>
        <population>All participants were used in primary and secondary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O2">
            <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
            <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
          </group>
          <group group_id="O3">
            <title>C. Placebo With Vitamin E 1200 IU/Day</title>
            <description>Placebo (with vitamin E 1200 IU/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Experiences: Insomnia: Moderate/Severe</title>
          <description>Number of participants with moderate/severe insomnia</description>
          <population>All participants were used in primary and secondary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All adverse experiences were tabulated by treatment group, severity and perceived relationship to study medication. Fisher's exact test was used to compare active treatment arms to the placebo arm with regard to the proportion of subjects experiencing a particular adverse experience.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9999.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>9999.99</ci_upper_limit>
            <estimate_desc>Odds ratio &gt;1 indicates a higher frequency in active treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected for a period of 2 years and 7 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="E2">
          <title>B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day</title>
          <description>Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)</description>
        </group>
        <group group_id="E3">
          <title>C. Placebo With Vitamin E 1200 IU/Day</title>
          <description>Placebo (with vitamin E 1200 IU/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastero-intestinal bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Accident with fractures and head trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident with fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Prostate cancer progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Benign prostatic hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic floor dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypersensitivity pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac catheterization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pacemaker battery replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Total knee replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastric banding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Transurethral resection of the prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="196"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The planned interim analysis for futility based on the first 300 subjects has reached the pre-specified termination criterion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M. Flint Beal, MD</name_or_title>
      <organization>Weill Medical College of Cornell University</organization>
      <phone>212-746-6575</phone>
      <email>fbeal@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

